SYS-CON MEDIA Authors: Lori MacVittie, RealWire News Distribution, Cynthia Dunlop, Mark O'Neill, Kevin Benedict

News Feed Item

Published Data, Stock Price Movements, and FDA Approvals - Research Report on Johnson & Johnson, Ariad Pharmaceuticals, PerkinElmer, BD, and Sanofi

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 13, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), PerkinElmer, Inc. (NYSE: PKI), Becton, Dickinson and Co. (NYSE: BDX), and Sanofi SA (ADR) (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On December 9, 2013, Janssen Research & Development LLC (Janssen), part of Janssen Pharmaceutical Companies of Johnson & Johnson (Johnson & Johnson), announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). According to Janssen, the study achieved its primary endpoint of safety, with data demonstrating treatment with ibrutinib as an initial therapy was associated with adverse events (AEs) that were predominantly Grade 1 or 2 in nature. Janssen further revealed that efficacy data demonstrates that 71% (95% CI, 52.0-85.8) of patients treated with ibrutinib achieved an objective response (defined as complete or partial response). Janssen also concluded that it is estimated that more than 95% of patients would be alive and progression-free at two years, though estimates of progression-free survival (PFS) and overall survival (OS) were not reached at the median follow up of 22.1 months. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Ariad Pharmaceuticals, Inc. Research Report

On December 10, 2013, Ariad Pharmaceuticals, Inc.'s (Ariad Pharmaceuticals) stock rose 3.50%, ending the day at $4.44. Over the previous three trading sessions, shares of Ariad Pharmaceuticals declined 2.84% compared to the Nasdaq Composite which gained 0.68% during the same period. The Full Research Report on Ariad Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


PerkinElmer, Inc. Research Report

On December 10, 2013, PerkinElmer, Inc.'s (PerkinElmer) stock rose 2.38%, ending the day at $39.61. Over the previous three trading sessions, shares of PerkinElmer gained 5.54% compared to the S&P 500 which gained 0.99% during the same period. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Becton, Dickinson and Co. Research Report

On December 3, 2013, BD Diagnostics, a segment of Becton, Dickinson and Co. (BD), announced that it has received FDA clearance to market the BD MAX StaphSR Assay for use on the fully-automated BD MAX System. BD Diagnostics reported that the assay, when used with eXTended Detection Technology, detects Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA directly from nasal swabs, including mecA dropout mutants and new strains of MRSA that may not be detected by other assays. Dr. Tobi Karchmer, Worldwide Vice President, Medical Affairs, BD Diagnostics, said, "Increased accuracy in determining patient colonization with either S. aureus or MRSA can enable clinicians to implement appropriate pre-surgical prophylaxis and direct appropriate utilization of isolation and decolonization." Dr. Karchmer added, "With results available in approximately two hours compared to two or more days for culture methods, the BD MAX StaphSR Assay provides accurate and timely information to help physicians ensure safe and appropriate management of surgical patients." The Full Research Report on Becton, Dickinson and Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:


Sanofi SA (ADR) Research Report

On December 5, 2013, Sanofi SA (ADR) (Sanofi) announced the results of a 24-week Phase IIIb clinical study showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or the main meal of the day. According to Sanofi, these results indicate that lixisenatide can effectively lower blood sugar at either time of administration. According to Sanofi, the results showed that a comparable reduction in body weight, regardless of the meal before which lixisenatide was administered, was achieved. Lastly, Sanofi informed that gastrointestinal tolerability was comparable regardless of time administration, with no cases of severe hypoglycemia in either arm. The Full Research Report on Sanofi SA (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.